------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->
Quark Biotech, Inc. Is the First Certified Service Provider for
Agilent Technologies' Array CGH (Comparative Genomic Hybridization)
Products
FREMONT, Calif., Quark Biotech, Inc. announced
today that the Company is the first Certified Service Provider for
Agilent
Technologies' (NYSE: A) microarrays to be certified for Array CGH
(Comparative
Genomic Hybridization) services. Quark was already a Certified
Service
Provider for Agilent gene expression microarrays.
This additional Agilent certification confirms Quark's continued
ability
to provide complete premium DNA microarray services. Certification
for the
Agilent program was granted once Quark's personnel completed a
training
program and the laboratory, as a whole, passed a rigorous set of
assessments.
The Certified CGH Service Quark provides includes sample receipt,
labeling and
the use of Agilent's CGH platform for hybridization and data
analysis.
"This Agilent certification will allow Quark to continue to
provide
dependable and high-quality microarray services," said Dr. Daniel
Zurr, Chief
Executive Officer of Quark Biotech, Inc. "Quark is very experienced
in the
microarray field and has been performing high volume microarray
experiments
based on its patented BiFAR(TM) platform for high-throughput
functional
profiling in the last six years."
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier
measurement
company and a technology leader in communications, electronics, life
sciences
and chemical analysis. The company's 28,000 employees serve
customers in more
than 110 countries. Agilent had net revenue of $7.2 billion in
fiscal year
2004. Information about Agilent is available on the Web at
www.agilent.com.
About Quark Biotech, Inc.
Quark Biotech, Inc. is a privately held development-stage,
biopharmaceutical company headquartered in Fremont, CA. Through
innovative
combination of gene silencing and DNA microarray technology, Quark
has
pioneered and patented its BiFAR(TM) platform for high-throughput
functional
profiling, allowing significant advances in the identification of
target genes
and proteins. This technology allows the company to develop
conceptually novel
drugs that provide previously unavailable benefits to patients.
Quark is
currently harvesting novel targets identified using this enabling
foundation
technology. Quark has focused development efforts on treatment of
fibrotic and
ischemic diseases of the eye, kidney and lungs, in indications with
clear
unmet medical needs.
Quark corporate product development teams and research
facilities are
based in Fremont, CA with research facilities also in Ness-Ziona,
Israel.
Additional information is available at www.quarkbiotech.com and at
www.quarklabs.com.
SOURCE Quark Biotech, Inc.
Web Site: www.quarklabs.com www.quarkbiotech.com
www.agilent.com
http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
